Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience

Am J Hematol. 2018 Feb;93(2):E47-E49. doi: 10.1002/ajh.24971. Epub 2017 Dec 4.

Authors

Jessica Slostad¹, Patrick Hoversten¹, Candace L Haddox¹, Kamila Cisak², Jonas Paludo², Ayalew Tefferi²

Affiliations

¹ Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
² Division of Hematology, Mayo Clinic, Rochester, Minnesota.

PMID: 29134683
DOI: 10.1002/ajh.24971

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Humans
Lymphohistiocytosis, Hemophagocytic / drug therapy*
Lymphohistiocytosis, Hemophagocytic / etiology
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines
Treatment Outcome

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib